# Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

> **NCT04511130** · PHASE2 · TERMINATED · sponsor: **Marker Therapeutics, Inc.** · enrollment: 92 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Stem Cell Transplantation

## Interventions

- **DRUG:** MT-401

## Key facts

- **NCT ID:** NCT04511130
- **Lead sponsor:** Marker Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-14
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 92 (ACTUAL)
- **Why stopped:** Despite a plan to enroll \~195-210 participants, the ARTEMIS study was closed due to the long vein-to-vein manufacturing timeline of MT-401 after 38 participants received the autologous MT-401.
- **Last updated:** 2025-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04511130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04511130, "Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04511130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*